



Update on Pathogenesis and Treatment of Kaposi's Sarcoma

Guest Editor:

Dr. Athanasia Tourlaki

1. Department of
Physiopathology and
Transplantation, University of
Milan, Milan, Italy
2. Dermatology Unit—
Fondazione IRCCS Ca' Granda,
Ospedale Maggiore Policlinico,
Via Pace, 9, Milan, Italy

Deadline for manuscript
submissions:

closed (5 April 2024)

Message from the Guest Editor

Dear Colleagues,

Kaposi's sarcoma is a rare, low-grade vascular neoplasm that is caused by Human Herpes Virus 8 (HHV-8) infection. In addition to HHV-8 infection, other factors are required in order to develop the disease, with the most important being impaired host immunity. Only a small number of infected subjects will develop Kaposi's sarcoma, and patients with acquired immune deficiency syndrome or under immune suppressive treatments are more likely to develop this neoplasm.

Since the discovery of HHV-8 in 1994, much has been learned about its epidemiology; however, many aspects regarding pathophysiology and their application into clinical practice are not yet fully clarified. Indeed, in the era of immunotherapy and targeted therapies for different types of cancer, chemotherapy is still the most common modality of treatment for patients with Kaposi's sarcoma.

This Special Issue will focus on the latest research results that contribute to the pathogenesis of Kaposi's sarcoma and its management and outcomes. Original research or review articles are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)